News & Events
First call for training modules
Training scientists in vaccine research and development (R&D) is crucial in order to sustain Europe’s excellence in this field. The TRANSVAC2 Consortium has set up training modules at leading European centers that can be combined to create customised international courses on vaccine R&D. Two rounds of customised training courses are planned. Participants can select topics as needed in their field of vaccine development and the timelines of the various modules are harmonized in a way that allows a logical continuation from one topic to the other.
Calls for application to the various training modules will be launched from June 2018 to February 2022, with subsequent deadlines one month after the launch of each call.
The first call is open from 1st June 2018 – 1st July 2018. It will cover for the following 2 training modules:
- M1 : Clinical vaccine development and Biomanufacturing, conducted at University of Oxford from 15-18 October 2018
- M2 : Human and veterinary vaccine development, conducted at University of Oxford from 19-23 November 2018
Participants will be selected by a course selection panel.
Courses are offered free of charge. However selected applicants will have to cover their own travel and visa expenses for some courses also their accommodation.
Candidates working in a European Union Member State or Associated Member State are eligible to apply. Candidates from other countries who are working in vaccine development projects funded by the European Commission (EC) or European and Developing Countries Clinical trial Partnership (EDCTP) will also be eligible to apply. Other candidates can also apply, but priority will be given to the groups mentioned above.
For more information about the training modules offered by TRANSVAC, the eligibility criteria and the application process, please visit: www.transvac.org
If you have any specific questions, you can contact the project management team at: firstname.lastname@example.org
Please spread information about this call among your colleagues working in or promoting research in vaccine development.
TRANSVAC is a new infrastructure project - funded by the European Commission in the context of Horizon 2020 - that aims to accelerate the development of effective vaccines urgently needed to address European and global health challenges with the ultimate goal to build an efficient and sustainable collaboration of experts and facilities to catalyse vaccine research in Europe.
TRANSVAC will offer high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use. These services are not restricted to any disease in particular. Except for the few cases indicated on the website, services will be offered free of charge! Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country.
The call for application is launched on 15 October 2017 and will remain open for the duration of the project (until April 2022) or until all services have been exhausted. Applications can be submitted at any time and will be processed at pre-defined cut-off dates occurring every four months. The first cut-off date is on 15 December 2017. Users of the services will be selected via an independent scientific peer review process. The selected projects will then be able to commence work within TRANSVAC shortly after notification.
The European Commission (EC), in the context of the Horizon 2020 Framework Programme, commits significant funding to TRANSVAC2, a European vaccine research and development (R&D) infrastructure.
Vaccines are one of the most successful and cost-effective public health tools for disease prevention. Their development however is time-consuming and complex, requiring a combination of specialised skills and technical capacities not readily available at a single organisation. In order to facilitate access to these skills and capacities, and to promote collaborations in the European vaccine landscape - aiming thereby to accelerate the development of safe, effective and affordable vaccines - the European Commission (EC), recently committed significant funding to TRANSVAC2.
Dr Odile Leroy, Executive Director of the European Vaccine Initiative (EVI) and coordinator of TRANSVAC2, said: “The TRANSVAC2 activities will further strengthen the vaccine R&D infrastructure in Europe and will thereby accelerate the development of effective vaccines that are urgently needed to address global health challenges”.
The TRANSVAC Workshop for Board of Stakeholders will take place in Brussels (Belgium) on the 21 June 2018.
The aim of the interactive workshop is to define the gaps in the current TRANSVAC roadmap and to pave the path for an updated TRANSVAC roadmap. Participants will build on the TRANSVAC and iPROVE roadmaps, taking into account the global activities, responses to emerging diseases, new technologies and other European and global initiatives. Invited guests will analyze the role of the EU in this “new” landscape and in sustaining EU vaccine projects by implementing a permanent research infrastructure for early vaccine development.
The first Annual Meeting of the TRANSVAC2 project will take place in Brussels (Belgium) on the 19 and 20 June 2018.
The TRANSVAC project will be presented at the International Society for Vaccines (ISV) congress at Institute Pasteur on 05 - 07 October 2017.
TRANSVAC @ Modern Vaccines Adjuvants & Delivery Systems - MVADS 2017 conference, Porto, Portugal
TRANSVAC @ ASTMH, ASTMH 66th Annual Meeting November 5-9, 2017, Baltimore, Maryland, USA